Association between indoxyl sulfate and skeletal resistance in hemodialysis patients

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 4, 2010, Pages 417-423

  Goto, Shunsuke ^a   Fujii, Hideki ^a   Hamada, Yasuhiro ^a   Yoshiya, Kunihiko ^b   Fukagawa, Masafumi ^a,c  

^a KOBE UNIVERSITY   (Japan)

^b Hara Genitourinary Hospital   (Japan)

^c TOKAI UNIVERSITY   (Japan)

Author keywords

Bone turnover; Hemodialysis; Indoxyl sulfate; Oxidative stress; Parathyroid hormone resistance

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALKALINE PHOSPHATASE; BONE SPECIFIC ALKALINE PHOSPHATASE; INDICAN; PARATHYROID HORMONE; PHOSPHATASE; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG; 8-OXO-7-HYDRODEOXYGUANOSINE; ACID PHOSPHATASE; BIOLOGICAL MARKER; DEOXYGUANOSINE; ISOENZYME; TARTRATE-RESISTANT ACID PHOSPHATASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE TURNOVER; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKELETAL RESISTANCE; ANALOGS AND DERIVATIVES; BLOOD; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; VERY ELDERLY;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; DEOXYGUANOSINE; FEMALE; HUMANS; INDICAN; ISOENZYMES; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARATHYROID HORMONE; REGRESSION ANALYSIS; RENAL DIALYSIS;

EID: 77955080616     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00813.x     Document Type: Article

References (51)

1. Fukagawa M, Kazama JJ, Shigematsu T. Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. Am J Kidney Dis 2001 38 : S152 5.
2. Disthabanchong S, Hassan H, McConkey CL, Martin KJ, Gonzalez EA. Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells. Kidney Int 2004 65 : 897 903.
3. Iwasaki-Ishizuka Y, Yamato H, Nii-Kohno T, Kurokawa K, Fukagawa M. Down-regulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant 2005 20 : 1904 1911.
4. Picton ML, Moore PR, Mawer EB et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 2000 58 : 1440 1449.
5. Ureña P, Ferreira A, Morieux C, Drüeke T, de Vernejoul MC. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. Nephrol Dial Transplant 1996 11 : 2008 2016.
6. Nakanishi S, Kazama JJ, Shigematsu T et al. Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am J Kidney Dis 2001 38 : S172 4.
7. Slatopolsky E, Finch J, Clay P et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000 58 : 753 761.
8. Iwasaki Y, Yamato H, Nii-Kono T et al. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 2006 21 : 2768 2774.
9. Nii-Kono T, Iwasaki Y, Uchida M et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007 71 : 738 743.
10. Yano S, Yamaguchi T, Kanazawa I et al. The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure. Nephrol Dial Transplant 2007 22 : 3160 3165.
11. Kazama JJ, Shigematsu T, Yano K et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002 39 : 525 532.
12. Yasuda H, Shima N, Nakagawa N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998 139 : 1329 1337.
13. Lund RJ, Davies MR, Brown AJ, Hruska KA. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 2004 15 : 359 369.
14. Vukicevic S, Basic V, Rogic D et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998 102 : 202 214.
15. Wang S, Chen Q, Simon TC et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003 63 : 2037 2049.
16. Niwa T, Takeda N, Tatematsu A, Maeda K. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 1988 34 : 2264 2267.
17. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003 63 : 1671 1680.
18. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol 2007 27 : 30 5.
19. Fujii H, Nishijima F, Goto S et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 2009 24 : 2089 2095.
20. Toyokuni S, Tanaka T, Hattori Y et al. Quantitative immunohistochemical determination of 8-hydroxy-2'-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest 1997 76 : 365 374.
21. Niwa T, Emoto Y, Maeda K, Uehara Y, Yamada N, Shibata M. Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patients. Nephrol Dial Transplant 1991 6 : 105 109.
22. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992 75 : 145 150.
23. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008 29 : 155 192.
24. Mozar A, Louvet L, Mentaverri R, Brazier M, Kamel S, Massy ZA. Indoxyl sulfate inhibits differentiation of osteoclast-like cells in vitro: possible role in adynamic bone disease. J Am Soc Nephrol 2008 19 : 509A abstract F-PO1778).
25. Kato A, Odamaki M, Hishida A. Blood 8-hydroxy-2'-deoxyguanosine is associated with erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 2003 18 : 931 936.
26. Maruyama Y, Nakayama M, Yoshimura K et al. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'- deoxyguanosine levels. Nephrol Dial Transplant 2007 22 : 1407 1412.
27. Handelman GJ, Walter MF, Adhikarla R et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001 59 : 1960 1966.
28. Tarng DC, Huang TP, Wei YH et al. 8-hydroxy-2'-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis 2000 36 : 934 944.
29. Stenvinkel P, Holmberg I, Heimbürger O, Diczfalusy U. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. Nephrol Dial Transplant 1998 13 : 2594 2600.
30. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 1996 125 : 360 368.
31. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000 15 : 1337 1345.
32. Hamano T, Tomida K, Mikami S et al. Usefulness of bone resorption markers in hemodialysis patients. Bone 2009 45 : S19 25.
33. Taal MW, Masud T, Green D, Cassidy MJ. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999 14 : 1922 1928.
34. Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type 1 N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997 43 : 2058 2063.
35. Ureña P, Bernard-Poenaru O, Ostertag A et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2003 18 : 2325 2331.
36. Nakai T, Kanbara N. Serum crosslinked N-terminal telopeptide of type 1 collagen for evaluation of bone loss in hemodialysis patients using dual-energy x-ray absorptiometry. Dial Transplant 2007 36 : 217 220.
37. Niwa T, Yazawa T, Ise M et al. Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats. Nephron 1991 57 : 84 8.
38. Ureña P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999 55 : 2141 2156.
39. Shidara K, Inaba M, Okuno S et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 2008 82 : 278 287.
40. De Francisco AL, Amado JA, Prieto M et al. Dialysis membranes and PTH changes during hemodialysis in patients with secondary hyperparathyroidism. Nephron 1994 66 : 442 446.
41. Satoh M, Yamasaki Y, Nagake Y et al. Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters. Kidney Int 2001 59 : 1943 1950.
42. Wu CC, Chen JS, Wu WM et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant 2005 20 : 1134 1139.
43. Calò LA, Naso A, Carraro G et al. Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol Dial Transplant 2007 22 : 1413 1419.
44. González-Diez B, Cavia M, Torres G, Abaigar P, Muñiz P. Effect of a hemodiafiltration session with on-line regeneration of the ultrafiltrate on oxidative stress. Comparative study with conventional hemodialysis with polysulfone. Blood Purif 2008 26 : 505 510.
45. Bervoets AR, Spasovski GB, Behets GJ et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003 41 : 997 1007.
46. Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996 7 : 506 512.
47. Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 2003 41 : 1052 1059.
48. Kahn SS, Iraniha MR. Diagnosis of renal osteodystrophy among chronic kidney disease patients. Dial Transplant 2009 38 : 45 57.
49. Magnusson P, Sharp CA, Magnusson M, Risteli J, Davie MW, Larsson L. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 2001 60 : 257 265.
50. Seibel MJ. Biochemical markers of bone turnover part 1: biochemistry and variability. Clin Biochem Rev 2005 26 : 97 122.
51. Ferreira MA. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed. Nephrol Dial Transplant 2000 15 (Suppl 5 8 14.